Ophthalmology Times Staff Reports

Anne L. Coleman, MD, president of the American Academy of Ophthalmology, offers a preview of its virtual 2020 annual meeting.

Researchers seeking fluid features, retinal integrity measures to test next step in image analysis and image interrogation in clinical trials.

David S. Boyer, MD, notes that the goal is to dry every patient out, with undertreatment the leading cause of a loss of visual acuity.

Results from TIME-2, a phase IIA study, support further development of combination treatment with subcutaneous injection of the Tie2 activator, AKB-9778 (Aerpio Therapeutics), plus intravitreous (IVT) anti-VEGF injection for diabetic macular edema.